Spectrophotometric Determination of Cycloserin in Bulk and Capsule Dosage form by Area Under Curve and First Order Derivative Methods

Dudhe P. B.*, Sonawane A. M.

Sinhgad College of Pharmacy, S.No. 44/1, Vadgaon (Bk.), Off Sinhgad Road, Pune-411 041, India

Abstract: It is a simple, precise and economical UV-spectrophotometric method has been developed for the estimation of Cycloserine in pharmaceutical dosage form. First method (A) applied was area under curve (AUC) in which area was integrated in the wavelength of range 212.0 nm-222.0 nm. Second method (B) was first order derivative spectrometric method. In which method absorbance at \( \lambda_{\text{min}} = 207.6 \text{nm} \), \( \lambda_{\text{max}} = 236.4 \text{nm} \) and zero cross= 217.0 nm was measured. The calibration curves were plotted for the method by using instrumental response at selected wavelengths and concentrations of analyte in the solution. Linearity observed in the concentration range of 5-25 µg/ml for the method. Capsule formulation was analyzed and the percentage of drug determined in the assays was 98.00-99.00%. Accuracy and precision studies were carried out and results were satisfactory obtained. The results of the analysis were validated statistically. Limit of detection (LOD) and limit of quantitation (LOQ) were determined for the method. The method was validated by the International Conference on Harmonization. All validation parameters were within the acceptable limit. The developed method was successfully applied to estimate the amount of Cycloserine in pharmaceutical formulation.

Keywords: Cycloserine, UV-spectrophotometry, Area Under Curve, First order derivative, Validation.

Introduction:

Cycloserine is a broad spectrum antibiotic. Cycloserine is an analog of amino acid D-alanine. It inhibits alanine racemase and D-alanine, D-alanine ligase which synthesizes the pentapeptide core using D-alanine both enzymes are essential in the synthesis of peptidoglycan and subsequently in cell-wall synthesis and maintains. It is most often used in combination with up to 5 drugs to treat. Cycloserine may be bactericidal or bacteriostatic, depending on local concentration effect as well as efficacy against the particular strain involved.

Fig. 1 Structure of cycloserine.
Chemically cycloserine is D-4-Amino-3-isoxazolidone as shown in Fig. 1. Molecular formula is C₃H₆N₂O₂ and it is molecular weight 102.09. Cycloserine which melting point on 147°C, it is white or pale yellow colour which is slightly hygroscopic in nature and degrade upon expose to humid atmosphere, So cycloserine should be kept in tightly closed container.  

Materials and Methods:

Apparatus and Instrumentation

Shimadzu UV 1800 (Japan) with matched quartz cells, connected to computer loaded with UV Prob Software. Single pan electronic balance (Shimadzu, ATY 224) was used for weighing purpose. Sonication of the solutions was carried out using an Ultrasonication (Spectralab UCB 40, India). Calibrated volumetric glasswares (Borosil) were used in this study.

Materials

Capsule of 250 mg strength were purchased from the local pharmacy in Pune under commercial available brand name CyclorinR (Lupin Laboratories Ltd.). Hydrochloric acid purchased from Loba Chemie Pvt Ltd, Mumbai (for preparation of 0.01N HCl). Double distilled water was used in this study.

Method development

Preparation of Standard Solution

The standard stock solution of cycloserine was prepared by transferring accurately weighed 100 mg of cycloserine to 100 ml volumetric flask containing 10 ml 0.01N HCl. Dissolve drug properly. Then volume was made up to the mark by using 0.01N HCl to gives concentration 1000 μg/ml. From this 10 ml of the solution was transferred to a 100 ml volumetric flask and make up the volume with 0.01N HCl to gives a concentration of 100 μg/ml which is standard stock solution and it is further diluted with 0.01 N HCl to get concentration 5-25 μg/ml.

Selection of wavelength range

The working standard solution of 15 μg/ml was scanned between 400 nm to 200 nm in UV spectrophotometer against 0.01N HCL as blank after baseline correction. Wavelength range selected around wavelength maxima 217.0 nm concentration (Figure 2).

Area under curve (Area calculation)

This method involves calculation of integrated value of absorbance with respect to wavelength in indicated range. Area calculation processing it emcalculates the area bounded by the curve and horizontal axis. Here horizontal axis represents baseline.

\[
\text{Area calculation} (\alpha + \beta) = \frac{\lambda_2 - \lambda_1}{\lambda_2} \text{Ad} \lambda 
\]

Whereas, \( \alpha \) is area of portion bounded by curved at a and a straight line connecting the start and end point, \( \beta \) is area of portion bounded by a straight line connecting the startand end point on curve data and horizontal axis, \( \lambda_1 \) and \( \lambda_2 \) are wavelenght representing start and end point of curve region. In this study area was integrated between wavelength ranges from212.0- 222.0 nm.

First Order Derivative Spectrophotometry (Method B):

In this method solution of Buspirone HCL (5-25 μg/ml) were separated by appropriate dilution of standard stock solution and scanned in the spectrum mode from 400 nm to 200 nm. The absorption spectra obtained were derivatised from first fourth order. First order derivative spectra were selected for analysis of drug. From spectra of drug the absorbance was measured at \( \lambda_{\text{max}}=207.6 \text{ nm, } \lambda_{\text{min}}=236.4.0 \text{ nm and zero cross } =217.0\text{ nm, amplitude difference (}dA\text{)} with respect to wavelength difference (}d\lambda\text{) was measured for the}
respective concentration of standard and was plotted against concentrations and regression equation was calculated.

Figure 2: Determination of $\lambda_{\text{max}}$ Cycloserine

Figure 3: Area under curve graph of 15 $\mu$g/ml Cycloserine solution

Figure 4: First order derivative spectra of Cycloserine
Preparation of calibration curve

Working solutions were prepared from standard stock solution by further dilution with methanol to obtain the concentration of 5, 10, 15, 20 and 25µg/ml, respectively. The solutions were scanned from 400 to 200 nm and area under curve (AUC) was integrated in the range of 212-222 nm. The calibration curve was plotted between area under curve against concentration(Figure 3).

Assay of capsule formulation

Twenty capsules were weighed accurately, open the capsule shells and remove the powder. Powder equivalent to 10 mg cycloserine was weighed and transferred to a 100 ml volumetric flask. It was dissolved in 100 ml 0.01N HCl and sonicated for 5 minutes to get homogeneous solution. Then it was first filtered through a 0.45µm whatman filter paper. A final concentration of 100 µg/ml of cycloserine was prepared. This solution was filtered through filter paper to remove some un-dissolved excipients. After filtration, from this 1.5 ml was taken and diluted to 10 ml with Distilled water which gives 15µg/ml solution This procedure repeated three times (Table 1).

<table>
<thead>
<tr>
<th>Method</th>
<th>Label claim (mg/cap)</th>
<th>Amount taken (mg)</th>
<th>Amount found (mg)</th>
<th>Assay %</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>250</td>
<td>10</td>
<td>9.853</td>
<td>98.53%</td>
</tr>
<tr>
<td>B</td>
<td>250</td>
<td>10</td>
<td>9.812</td>
<td>98.12%</td>
</tr>
</tbody>
</table>
Table 2: Calibration data of Cycloserine

<table>
<thead>
<tr>
<th>Concentration(µg/ml)</th>
<th>Method A (Area under curve)</th>
<th>Method B (First order derivative)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 µg/ml</td>
<td>0.02822</td>
<td>0.000246</td>
</tr>
<tr>
<td>10 µg/ml</td>
<td>0.05745</td>
<td>0.000479</td>
</tr>
<tr>
<td>15 µg/ml</td>
<td>0.09061</td>
<td>0.000597</td>
</tr>
<tr>
<td>20 µg/ml</td>
<td>0.11718</td>
<td>0.000846</td>
</tr>
<tr>
<td>25 µg/ml</td>
<td>0.14829</td>
<td>0.000999</td>
</tr>
</tbody>
</table>

Table 3: Result of precision

<table>
<thead>
<tr>
<th>Precision</th>
<th>Method A (%RSD)</th>
<th>Method B (%RSD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repeatability</td>
<td>0.7654</td>
<td>0.3021</td>
</tr>
<tr>
<td>Intraday</td>
<td>0.5664</td>
<td>0.7685</td>
</tr>
<tr>
<td>Interday</td>
<td>0.9835</td>
<td>0.6839</td>
</tr>
</tbody>
</table>

In method A, the concentration of Cycloserin was determined by measuring area under curve in the range of 212.00nm to 222.00nm and values were substituted in the respective formula to obtain concentration.

In method B first order derivative spectrophotometry the concentration of solution determined by measuring absorbance at $\lambda_{\text{min}}=207.60\text{nm}$, $\lambda_{\text{max}}=236.4\text{nm}$ and zero cross=217.00nm. This procedure was repeated in triplicate.

Table 4: Recovery Study of Cycloserine

<table>
<thead>
<tr>
<th>Test(µg/ml)</th>
<th>Accuracy level</th>
<th>Amount of standard drug added (µg/mL)</th>
<th>Method A % Recovery</th>
<th>Amt. of Drug Std. (µg)</th>
<th>Method B % Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>15µg/ml</td>
<td>80%</td>
<td>12</td>
<td>99.94</td>
<td>12</td>
<td>98.90</td>
</tr>
<tr>
<td></td>
<td>100%</td>
<td>15</td>
<td>99.56</td>
<td>15</td>
<td>99.76</td>
</tr>
<tr>
<td></td>
<td>120%</td>
<td>18</td>
<td>98.03</td>
<td>18</td>
<td>99.56</td>
</tr>
</tbody>
</table>

Table 5: LOD and LOQ of Cycloserine

<table>
<thead>
<tr>
<th>Methods</th>
<th>Method A</th>
<th>Method B</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOD</td>
<td>0.08966</td>
<td>0.4919</td>
</tr>
<tr>
<td>LOQ</td>
<td>0.2716</td>
<td>1.4907</td>
</tr>
</tbody>
</table>

Method validation

The objective of validation of an analytical procedure is to demonstrate whether the procedure is suitable for its intended purpose. The proposed method was validated for various parameters such as Linearity, Accuracy, Precision, Limit of detection (LOD) and Limit of Quantitation (LOQ) according to ICH Q2 (R1) guideline.[8]

Linearity and Range

The linearity was determined by using working standard solutions between 05-25µg/ml. The spectrums of these solutions were recorded and area under curve was integrated in wavelength range 212-222 nm. Calibration curve of Area under curve versus Concentration was plotted after suitable calculation and simple linear regression was performed (Figure3). Regression equation and correlation coefficient were obtained. The range of solution has been decided according to statistical parameters of generated equation.
Method Precision

Repeatability

The precision of the method was checked by repeatedly injecting (n=6) standard solutions of Cycloserine (15 μg/mL). Area under curve of each of these solutions was measured in the range of 212-222 nm. Percentage relative standard deviation (%RSD) was calculated (Table 3).

Intermediate Precision (Reproducibility)

The intra-day and inter-day precision of the proposed method was determined by analyzing the corresponding responses 3 times on the same day and on 3 different days over a period of 1 week for 3 different concentrations of standard solutions of Cycloserine (5, 10 and 15 μg/mL). The results were reported in terms of relative standard deviation (%RSD). The results were tabulated in (Table 3).

Limit of Detection (LOD) and Limit of Quantitation (LOQ)

Six sets of known concentrations (5-25 μg/ml) were prepared. Calibration curves were plotted for each set. LOD and LOQ were calculated using the formulae as:

\[
LOD = 3.3 \frac{SD}{S} \\
LOQ = 10 \frac{SD}{S}
\]

Where, SD is standard deviation of y-intercept of the calibration curves, S is mean slope of six calibration curves.

Accuracy

The accuracy for the analytical procedure was determined at 80%, 100% and 120% levels of standard solution. Area under curve was measured in the range of 212-222 nm and results were expressed in terms of % recoveries. Three determinations at each level were performed and % RSD was calculated. The results were tabulated in (Table 4).

Results and discussion

An attempt was made to develop a simple and specific AUC spectrophotometric method for the determination of cycloserine in capsule dosage form. The generated regression equation was

\[\int_{212}^{222} A d\lambda = 0.006x - 0.0016 \quad R^2 = 0.9992\]

Where, \(\int_{212}^{222} A d\lambda\) is area under curve between 212 to 222 nm, C is concentration and \(R^2\) is correlation coefficient. The \(R^2\) value as 0.9992 indicate that developed method was linear. The proposed method was found to be precise as % R.S.D values for intraday as well interday precision were satisfactory. The drug at each of the 80%, 100% and 120% levels showed good recoveries (98% to 101%). Hence, it can be said that this method was accurate. The result of the analysis of pharmaceutical formulation by the developed method was consistent with the label claim, highly reproducible and reliable. The method can be used for the routine analysis of the Cycloserine in capsule dosage form. The validation parameters are summarized in (Table 6).
Table 6: Summary of Cycloserine

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Method A</th>
<th>Method B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Range (nm)</td>
<td>212.0-222.0</td>
<td>310 nm</td>
</tr>
<tr>
<td>Linearity range (µg/ml)</td>
<td>5-25 µg/ml</td>
<td>5-25 µg/ml</td>
</tr>
<tr>
<td>Regression equation</td>
<td>(0.006x - 0.0016)</td>
<td>(4E-05x + 7E-05)</td>
</tr>
<tr>
<td>Slope (m)</td>
<td>0.0016</td>
<td>7E-05</td>
</tr>
<tr>
<td>Intercept (c)</td>
<td>0.006</td>
<td>4E-05x</td>
</tr>
<tr>
<td>Correlation coefficient (R^2)</td>
<td>0.9992</td>
<td>0.9908</td>
</tr>
<tr>
<td>Repeatability</td>
<td>0.7654</td>
<td>0.3021</td>
</tr>
<tr>
<td>Intraday</td>
<td>0.5664</td>
<td>0.7685</td>
</tr>
<tr>
<td>Interday</td>
<td>0.9835</td>
<td>0.6839</td>
</tr>
<tr>
<td>Accuracy (Mean % Recovery)</td>
<td>99.18</td>
<td>99.41</td>
</tr>
<tr>
<td>LOD</td>
<td>0.08966</td>
<td>0.4919</td>
</tr>
<tr>
<td>LOQ</td>
<td>0.2716</td>
<td>1.4907</td>
</tr>
</tbody>
</table>

Results and Discussion

An attempt was made to develop a simple and specific AUC and first order derivative spectrophotometric method for the determination of Cycloserine in capsule dosage form. The generated regression equations were,

\[
\text{Method A} - \int_{212}^{222} \frac{dA}{d\lambda} = 0.006x-0.0016 \quad R^2=0.9992
\]

\[
\text{Method B} - \int \frac{dA}{d\lambda} = 4E-05x+7E-05
\]

Where \(\int_{212}^{222} \frac{dA}{d\lambda}\) is area under curve between 212.00 nm – 222.00 nm, \(\frac{dA}{d\lambda}\) is amplitude difference, \(x\) is concentration and \(R^2\) is correlation coefficient. The \(R^2\) values were 0.9992 and 0.9908 for Method A and B respectively indicated that developed methods were linear. The proposed methods were found to be precise as % RSD values for intraday as well as interday precision were satisfactory. The drug at each of the 80 %, 100 % and 120 % levels showed good recoveries that is in the range of 98.00 to 99.00%, hence it could be said that these methods were accurate. The LOD and LOQ were calculated as 0.08966 µg/ml and 0.2716µg/ml for Method A and 0.4917µg/ml and 1.4907µg/ml for Method B respectively. The results of analysis of pharmaceutical formulation by the developed methods were consistent with the label claim, highly reproducible and reliable and hence the methods can be used for the routine analysis of the Cycloserine in capsule dosage forms. The validation parameters for Method A and Method B are summarized in Table 6.

Conclusion

The two spectrophotometric methods were developed and validated as per ICH guidelines Q2 (R1). The proposed methods were found to be simple, rapid, precise, consistent and accurate for determination of Cycloserine in capsule dosage form. Results suggest that these methods can be used for routine estimation of Cycloserine in bulk and pharmaceutical dosage forms.

Acknowledgements

The authors would like to acknowledge the staff and management of the Sinhgad College of Pharmacy, Pune for providing all the facilities to carry out the present research work.
References:


